Two-Drug combo shows promise in Hard-to-Treat leukemia, but trial halted early

NCT ID NCT03708003

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested a two-drug combination (ibrutinib followed by venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatment. The goal was to see if the drugs could work together to clear cancer cells from the body and allow patients to take breaks from medication. The trial was terminated early, but the approach aimed to reduce side effects and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • IOSI - Ospedale San Giovanni

    Bellinzona, 6501, Switzerland

  • Inselspital

    Bern, 3010, Switzerland

  • Kantonsspital Aarau

    Aarau, CH-5001, Switzerland

  • Kantonsspital Graubünden

    Chur, 7000, Switzerland

  • Kantonsspital Liestal

    Liestal, CH-4410, Switzerland

  • Kantonsspital Münsterlingen

    Münsterlingen, 8596, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • Luzerner Kantonsspital

    Lucerne, 6000, Switzerland

  • Spital STS AG Thun

    Thun, 3600, Switzerland

  • Universitätsspital Basel

    Basel, 4031, Switzerland

  • Universitätsspital Zürich

    Zurich, 8091, Switzerland

Conditions

Explore the condition pages connected to this study.